Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00430846 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies (NCT00430846)

Trial Description
Phase I study to define the safety profile and pharmacokinetic parameters of brentuximab vedotin (also known as SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: 
    • Non-Hodgkin Lymphoma
    • Hodgkin Disease
    • Large-Cell Anaplastic Lymphoma
  • Interventions:
    • Drugs used in this trial
      • Non-Hodgkin
  • Phase: I
  • Enrollment: 45
  • Start: November 2006
  • Completion: July 2009
  • Last verified: December 2014

Study Schematic

NCT00430846 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar